Clinical trial
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell…
NCT00005982 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00005982 |
|---|---|
| Title | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma |
| Official title | Phase II Study of 506U78 (NSC #686673) in Patients With Previously Treated Cutaneous T-Cell Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome |
| Intervention type | Drug, Other |
| Interventions | nelarabine, pharmacological study |
| Enrollment | 35 |
| Start date | Apr 1, 2000 |
| Primary completion | Jul 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: